Anti-Myeloperoxidase 抗体

• ICC

AbReview36632****

Immunocytochemistry - Anti-Myeloperoxidase antibody (AB9535)

ab9535 staining of multinucleated cell (Blue) in human blood smear. Antibody was used at 1/200 for 1 hour at 21°C.

Image courtesy of Carl Hobbs, Kings College London, U.K

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Myeloperoxidase antibody (AB9535)

Immunohistochemical analysis of formalin-fixed, paraffin-embedded human B cell lymphoma tissue, staining Myeloperoxidase with ab9535.

• IHC

CiteAb

Immunohistochemistry - Anti-Myeloperoxidase antibody (AB9535)

Myeloperoxidase immunohistochemistry using Anti-Myeloperoxidase antibody ab9535. Publication image and figure legend from Rymaszewski, A. L., Tate, E., et al., 2014, Cancers (Basel), Pubmed 24821130.

Genetic deletion of MPO slows tumor growth in a heterotopic syngeneic tumor model. WT and MPO-/- C57BL/6J mice were injected in the right flank with Lewis Lung Carcinoma cells. (A) Tumor volume was monitored over the course of 17 days. MPO-/- mice exhibited smaller tumors compared to WT. Wild type mice treated with KYC were no different than PBS treatment; (B) Tumors were surgically resected and weighed on day 17. The weight of tumors from MPO-/- mice was significantly smaller compared to WT mice; (C) Representative images of tumors stained for Ly6G, MPO and apoptosis marker cleaved caspase-3 (4x); (D) Representative images of non-necrotic sections were immunostained for the neutrophil marker Ly6G, MPO, cleaved caspase-3 and proliferation marker Ki-67 (40x); (E) Tumor infiltrating neutrophils were elevated in MPO-/- mice compared to WT and KYC treated mice.